There was a significantly higher proportion of EGFr+ tumours in the endocrine failure group compared with the control population (P<0.001).
The anti-oestrogen drug tamoxifen, and the aromatase inhibitor aminoglutethimide, have been extensively tested in metastatic breast cancer with overall objective remission rates of around 30% (Cole & Todd, 1976; Ward, 1973; Murray & Pitt, 1981; Harris et al., 1986a,b) . The lack of serious toxicity in the case of tamoxifen has made this a particularly attractive therapy where quality of life was as important as prolongation (Stewart et al., 1980) . In advanced disease ER status predicts response to endocrine therapy (Block et al., 1975; McGuire et al., 1975; Roberts et al., 1978) .
The proportion of patients with ER positive primary breast cancers increases with age such that about 70% of patients over 70 years of age have ER positive tumours (Allegra et al., 1979; Elwood & Godolphin, 1980) . These observations may in part account for the relatively good prognosis for some elderly patients with breast cancer.
Tamoxifen had proved useful in the treatment of many elderly patients with advanced or metastatic breast cancer (Ingle et al., 1981; Legha et al., 1978) . The use of pharmacological endocrine manipulation as the sole treatment of primary operable breast cancer in the elderly has been reported in several small studies (Preece et al., 1982; Hellenberg et al., 1982; Bradbeer, 1985; Allan et al., 1985; Horgan et al., 1986) , and in one randomised prospective study (Gazet et al., 1988) , to be an alternative to surgery. Steroid receptor status at relapse was not reported in these studies but in one (Allan et al., 1985) the response rate for ER positive tumours was found to be similar to the overall response rate.
The use of primary endocrine therapy for many elderly patients with operable breast cancer became our standard practice in mid-1984. However, not all elderly patients will respond to tamoxifen and some relapse rapidly (within 6 months) without any initial control of tumour growth. We have shown previously that EGF receptor status is a strong prognostic factor in primary breast cancer (Sainsbury et al., 1987 EGFr to age, relapse in elderly patients on primary endocrine therapy, and its role in predicting tumour recurrence in elderly patients treated by primary surgery.
Patients and methods
Fifty-one patients over seventy years and ten in their late sixties with severe intercurrent medical illness or severe psychological aversion to mastectomy who were otherwise considered to have primary operable breast cancer were offered primary endocrine therapy. Patients with proven distant metastases at the time of presentation, as assessed by biochemical and clinical criteria, were excluded from this study.
The study population comprised 61 patients. The median age was 77 years (range 64-96) and all patients were over 15 years postmenopausal. All the patients had confirmation of the diagnosis by fine needle aspiration biopsy.
Primary endocrine therapy with either tamoxifen (20mg once daily) (60 patients) or low dose aminoglutethimide (125mg twice daily) and hydrocortisone (20mg twice daily) was used. Three patients received low dose aminoglutethimide, one as primary therapy and two who had rapidly progressed on tamoxifen.
Patients were assessed at three monthly intervals and response was defined using UICC criteria (Hayward et al., 1977 (1988), 58, 810-814 separate, but cytologically proven, axillary lymph node metastasis. At progression she was treated by radical radiotherapy with an irridium implant boost at the site of the primary.
A control population of 33 elderly women, median age 72 years (range 64-86) with primary operable breast cancer treated by primary surgery comprised historical controls who received their treatment in the period immediately prior to our adoption of primary endocrine therapy in this age group and a small number of elderly patients under the care of consultants not involved in this trial. Although this group was slightly younger (median age 72 years compared with 77 years in the primary endocrine therapy group) there was no difference in initial tumour size or disease stage compared with the endocrine therapy group (Table I) .
Following surgical excision for locally progressive disease oestrogen receptor analysis was performed by the dextran coated charcoal (DCC) method. A level of 5 fmol mg-1 cytosol protein was taken as the lower limit of positivity for the DCC assay (Nicholson et al., 1988) .
The DCC assay for ER was known to be affected by pretreatment with tamoxifen (Taylor et al., 1982; Hull et al., 1983; Crawford et al., 1987 Epidermal growth factor receptor (EGFr) analysis was performed on 20/22 patients with progression on primary endocrine therapy using a two point 1-125 EGF radioreceptor assay with lOfmolmg-1 the lower limit of binding considered positive (Nicholson et al., 1988) .
All the control patients had ER and EGFr assays performed on their primary tumours. None had received prior endocrine therapy, therefore, ER immunohistochemistry was not necessary for assessment of these tumours.
Statistics
Peto life table analysis was performed using a Logrank test (Peto et al., 1977) with a programme designed for the BBC microcomputer by Dr B. Angus (Dept. Pathology, University of Newcastle upon Tyne). The Chi-square and Fisher's Exact tests were used to compare populations in the various subgroups.
Results
Response to endocrine therapy Of sixty-one patients commenced on primary endocrine therapy eleven achieved a complete response (CR), twentyfour a partial response (PR), twelve had static disease (SD) and fourteen had progressive disease (PD) ( Table II) .
For patients achieving a partial response the median time to establish this was 3 months, and for those achieving a complete response it was 10 months.
There was only one death in the patients with a continuing response. This patient was 91 at presentation and died of causes unrelated to her breast cancer. There were 7 deaths in the group undergoing salvage surgery, all from disseminated breast cancer.
Comparison of outcome in control vs. primary endocrine patients Recurrence for the primary endocrine patients was con- (Figure 2a ). In contrast, this early relapse group was composed of similar numbers of ER+ and ER-tumours (Figure 2b) . None of the EGFr + patients had any objective response prior to disease progression. A comparison of receptor status among the 'salvage' surgery patients is shown in Table III . There is a significant association with EGFr positivity and failure of any response to endocrine therapy. In contrast 6/7 relapsers after an initial response were ER+ at relapse and none were EGFr+.
The proportion of patients with EGFr + tumours was significantly different in those progressing on primary endocrine therapy from that found in the general elderly population, as exemplified by the primary surgical control group (Table III) EGFr status: association with recurrence after 'salvage surgery' and death in primary endocrine failure patients EGFr status was significantly associated with recurrence after salvage surgery and death (timed from the start of endocrine therapy) for the endocrine progressive disease patients (chi-square for recurrence = 7.92, P < 0.005, Figure  3a , and death=4.31, P<0.05, Figure 3b ). There was no such association for ER status. In the control primary surgery patients EGFr status also predicted recurrence (chi-square=7.11, P<0.01, Figure 4) . The relationship between overall survival and EGFr status, however, did not reach significance. ER status did not predict recurrence or death in the control group.
The RFS of the EGFr positive endocrine progressive disease patients was similar to the EGFr positive control Fisher's Exact 2 x 2, P <0.1; Chi-square no responses vs. controls (2 x 2) =1.239, not significant EGFr + 10 0 6 EGFr-2 8 27
Fisher's Exact 2 x 2, P <0.001; Chi-square no response vs. controls (2 x 2)= 13.58, P<0.001.
patients and likewise the EGFr negative patients in both groups had similar recurrence free survivals (Figure 4 ). (Nicholson et al., 1988) . The proportion of patients with ER+ tumours is known to be related to age (Elwood & Godolphin, 1980) . We have therefore compared ER and EGFr expression with age in our previously published series of primary operable breast cancers (Nicholson et al., 1988 ER status is maintained at all ages (Table IV) and there is a significant inverse correlation of EGFr with age (P<0.01). Previous follow-up studies had shown that EGFr status of primary operable breast tumours was associated with a poorer prognosis (Sainsbury et al., 1987) . The current study has confirmed these findings in an elderly primary surgical control population.
The data from this study has shown an association between EGFr status at the time of 'salvage' surgery and reduced RFS (time from start of primary endocrine therapy to post-surgical relapse) and OS in patients whose disease had progressed on primary endocrine therapy.
EGFr status was significantly associated with a lack of any response to primary endocrine therapy. Twenty out of twenty-two patients undergoing 'salvage' surgery for endocrine progressive disease had EGFr analysis. Ten of twelve patients whose tumours had shown no response to primary endocrine therapy were EGFr + compared with none of eight patients whose tumours progressed after an initial response (P=0.0014). There was no such association with ER status which was similarly not associated with either RFS or OS in either the endocrine progressive disease or control populations.
Since 9/11 tumours progressing on primary endocrine therapy within six months of the start of therapy were EGFr + this suggests that EGFr expression is associated with rapid failure of endocrine therapy. It was not possible to evaluate EGFr status before therapy in this particular group because the aim was to minimise traumatic intervention and perform fine needle aspiration biopsy before starting endocrine therapy.
Surgical treatment at an earlier stage when the primary tumour was smaller would be less traumatic for these elderly patients. However, since surgical failures and endocrine therapy failures which have EGFr + tumours have very similar prognosis, surgery of endocrine failures per se seems to have relatively little to offer other than debulking tumour and improving the chances of local control. At relapse following surgery, or perhaps even as an adjuvant therapy, a mild short course chemotherapy, such a mitozantrone, should be evaluated (Cantwell et al., 1987) .
The value of EGFr data in identifying a population of elderly breast cancer patients who progressed rapidly on primary endocrine therapy and surgery highlighted the need to develop non-excisional methods of receptor analysis. The radioreceptor assay for EGFr used in this study required Il more tumour material than could be provided by needle core biopsy. Immunological methods using a monoclonal antibody to the EGF receptor (Waterfield et al., 1982) to stain fine needle aspiration biopsy smears may prove to be useful. S. Nicholson is funded by the North of England Cancer Campaign.
